Iceland Genomics and Myriad form cancer gene deal:
This article was originally published in Clinica
Biopharmaceutical firm Iceland Genomics has entered into cancer gene discovery collaboration with Myriad Genetics. Under the terms of the agreement, Myriad will supply genetic markers, which Reykjavik-based Iceland Genomics will use with its proprietary sample collection to help Myriad localise and identify a cancer gene. Iceland Genomics will receive research support and milestone payments and royalties on any diagnostic or therapeutic products that are developed by Myriad on the basis of the gene, said the firm. Financial details of the collaboration were not disclosed.